Plain-English translation of NCT06123494 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new drug called to see if it works better than standard chemotherapy for people with advanced stomach cancer that has progressed despite prior HER2-targeted treatment. Half of the participants will receive this new medication, while the other half will receive chemotherapy chosen by their doctor. The goal is to determine whether this medication offers better outcomes with manageable side effects.
People with advanced stomach cancer often develop resistance to their first line of treatment, leaving them with limited options. This trial is testing whether this medication could provide a better second-line treatment option for these patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication or your doctor's choice of standard chemotherapy. You'll visit the clinic regularly for treatment administration, blood tests, and imaging scans to monitor how well the treatment is working and check for side effects. The study will continue until your cancer progresses or you experience unacceptable side effects, with the goal of enrolling 360 participants total.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China